The information below has been supplied by dairy marketers and other industry organizations. It has not been edited, verified or endorsed by Hoard’s Dairyman.

Phibro Animal Health Corporation has expanded production capacity of its Animate® nutritional specialty product with the opening of a new manufacturing plant in Quincy, Illinois. Animate is a patented anionic mineral supplement which, when used as recommended, may lead to enhanced health and performance of transition dairy cows by helping to reduce the incidence of clinical and subclinical hypocalcemia.

“The new, high-efficiency plant enables Phibro to keep pace with growing demand in the U.S. and international dairy markets,” said Ken Zanzalari, Phibro’s Animate Product Manager. “Animate use continues to expand as dairy producers seek nutritional strategies to help maximize transition cow performance and prepare their herds for a profitable lactation. With our current Animate production facility already at full capacity, the addition of a second plant ensures our ability to meet anticipated growth.”

The 63,000 square-foot facility includes production, packaging, warehousing and space for a product development laboratory and pilot plant. This is the second new plant that Phibro has built for Animate production in the last three years.

Dean Warras, Phibro’s President, Animal Health & Nutrition, North America, noted that the new Animate plant reflects Phibro’s partnership with the dairy industry through its commitment to invest wherever necessary to meet demand. “Dairy producers have come to rely on Animate, as well as our dairy technical expertise and on-farm service model, in the critical area of transition cow performance. We are committed to providing some of the most advanced solutions in the industry to help make dairy cows healthier and more profitable,” he said.

Animateis recommended to be fed to pre-partum dairy cows a minimum of 21 days before calving to help maintain normal serum calcium status during the critical days before, during and after calving which may help reduce the risk of clinical and subclinical hypocalcemia, conditions which can result in significant health issues and reduced milk production. Because of its high palatability, concentrated source of anions and complete formulation, Animate can be fed as part of a fully-acidified negative DCAD (dietary cation anion difference) diet without reducing dry matter intake, leading to increased milk yield.

This communication contains forward-looking statements, which reflect Phibro’s current views with respect to business plans or prospects, the transactions described herein, and other future events. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.